Transformative Moments in Oncology: Curative Combination Therapy for Cancer
- Vincent DeVita
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
-
DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881-895.
- Moore MR, Jones SE, Bull JM, et al. MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients. Cancer. 1973;32(1):52-60.
-
DeVita VT, Canellos GP, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet. 1975;1(7901):248-250.
-
Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295-1306.
-
Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-259.
- Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
- Tran E, Turcotte S, Gros A, et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science. 2014;344(6184):641-645.
-
Hanahan D, Weinberg RA. Hallmarks of Cancer. An organizing principle for cancer medicine. In DeVita VT, Jr, Lawrence TS, Rosenberg SA (eds). DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2014; chap 2:24-44.
Disclosure statements are available on the authors' profiles: